|1.||Multiple Endocrine Neoplasia Type 2a (MEN 2)
|3.||Coronary Artery Disease (Coronary Atherosclerosis)
|4.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
|5.||Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
|1.||Takahashi, M: 5 articles (04/2014 - 01/2000)|
|2.||Santoro, Massimo: 5 articles (08/2013 - 06/2002)|
|3.||Wells, Samuel A: 5 articles (08/2013 - 01/2007)|
|4.||Iwashita, T: 4 articles (04/2014 - 01/2000)|
|5.||Moley, Jeffrey F: 4 articles (09/2013 - 05/2002)|
|6.||Miccoli, Paolo: 3 articles (06/2015 - 12/2007)|
|7.||Stratakis, C A: 3 articles (09/2014 - 05/2000)|
|8.||Ichihara, M: 3 articles (04/2014 - 02/2000)|
|9.||Qiao, S: 3 articles (04/2014 - 02/2000)|
|10.||Saarma, Mart: 3 articles (08/2011 - 05/2007)|
|1.||N- (4- bromo- 2- fluorophenyl)- 6- methoxy- 7- ((1- methylpiperidin- 4- yl)methoxy)quinazolin- 4- amine (ZD6474)IBA
08/01/2013 - "Using an innovative trial design and selecting patients based on target gene expression, we conclude that vandetanib 100 mg/m(2)/d is a well-tolerated and highly active new treatment for children and adolescents with MEN2B and locally advanced or metastatic MTC."
08/01/2013 - "Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma."
01/01/2015 - "Data from 13 patients with multiple endocrine neoplasia type 2B (MEN 2B) and MTC were analyzed [6 M, 7 F, median age 13.0 y (9.1-17.3)] Eleven patients (85%) had undergone prior thyroidectomy and all received single-drug therapy with vandetanib for > 6 months. "
06/01/2011 - "There is indeed specificity for different RET mutations, with XL184 being the most potent inhibitor in MEN2A and PTC and vandetanib the most effective in MEN2B in vitro. "
06/01/2011 - "We aimed to compare the effect of four TK inhibitors (axitinib, sunitinib, vandetanib, and XL184) on cell proliferation, RET expression and autophosphorylation, and ERK activation in cell lines expressing a MEN2A (MTC-TT), a MEN2B (MZ-CRC-1) mutation, and a RET/PTC (TPC-1) rearrangement. "
08/01/1996 - "To determine whether coronary atherosclerosis develops with age in asymptomatic patients with familial hypercholesterolemia (FH) and whether long-term cholesterol-lowering therapy is effective for primary prevention of coronary artery disease (CAD) in such patients, 13 patients with heterozygous FH (10 men, 3 women, aged 34 to 66 years) were examined by coronary angiography, and followed up for 5.8 +/- 3.4 years. "
01/01/2011 - "Two independent reviewers selected studies that met the following criteria: (1) randomized controlled trials, (2) aerobic exercise combined with diet recommendations (saturated/trans fat intake less than 10% of total calories and cholesterol less than 300 mg/day and/or fiber intake ≥ 25 g/day in women and ≥ 35 grams per day in men), (3) intervention ≥ 4 weeks, (4) humans ≥ 18 years of age, (5) published studies, including dissertations and Master's theses, (6) studies published in any language, (7) studies published between January 1, 1955 and May 1, 2009, (8) assessment of one or more of the following lipid and lipoprotein concentrations: total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), ratio of TC to HDL-C, non-HDL-C, low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG). "
|3.||Vitamin EFDA LinkGeneric
|4.||Factor IX (PTC)FDA LinkGeneric
12/07/1995 - "We have compared the biological and biochemical activity of the TK domains of the wild type and MEN 2B Ret in the context of the RET/PTC. "
08/01/2004 - "We tested on thyroid follicular cells the transforming activity of RET(C634S), RET(K603Q), another mutant identified in a kindred with both PTC and MTC, RET(C634R) a commonly isolated allele in MEN2A, RET(M918T) responsible for MEN2B and also identified in kindreds with both PTC and MTC, and RET/PTC1 the rearranged oncogene that characterizes bona fide PTC in patients without MTC. "
10/01/2000 - "Moreover, regardless of the nature of the underlying activating mutation, the concomitant phosphorylation of Y1015 and Y1062 is a common feature of the various oncogenic RET products (MEN2A, MEN2B, and PTC). "
03/01/2000 - "It is clear that RET is responsible for MEN 2A, MEN 2B, FMTC, and PTC. "
12/01/2004 - "Ten patients were papillary carcinoma (PTC) bearers, four had medullary carcinoma (MTC; three of them with MEN-2B) and one had follicular carcinoma. "
06/01/2007 - "We examined the efficacy of bendamustine in 15 pretreated patients (12 men, 3 women, median age 69 years) with acute myeloid leukaemia (AML) or myelodysplastic syndromes (MDS) 3 AML, 5 sAML, 5 CMML II, 1 RAEB II. Patients belonged to the following cytogenetic groups: 3 complex abnormal karyotypes, 7 normal karyotypes, 1 case with 20q- as sole anomaly and 4 single aberrations. "
07/01/2005 - "In Argentina, RET testing excluding MEN 2B was always reported with a mutation at codon 634, with one exception: we described a novel mutation T > C transition at codon 630 (C630R), the family to which we extend the study in the present report. "
11/01/1997 - "In this study, we demonstrate the presence of germline codon 883 mutation (A883F) in 2 of 3 unrelated MEN 2B cases without codon 918 mutation. "
05/01/2013 - "All patients with a codon 918 mutation (MEN2B) developed PHEO by age 56 years. "
01/01/2012 - "A second point mutation at codon 883 has been found in 2%-3% of MEN 2B cases. "
05/01/2009 - "In two families of MEN 2B, all carried the mutation at codon 918 (M>T). "
|7.||Protein Isoforms (Isoforms)IBA
01/23/1997 - "Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations."
02/20/1997 - "In this study, we have demonstrated that the transducing adaptor molecule Shc is recruited and activated by both Ret isoforms and by the rearranged cytoplasmatic Ret/ptc2 oncoproteins as well as by the membrane bound receptor activated by MEN2A or by MEN2B associated mutations. "
01/23/1997 - "In this study, we have introduced a MEN 2A mutation (Cys634-->Arg) and the unique MEN 2B mutation (Met918-->Thr) in two RET isoforms of 1114 and 1072 amino acids which differ in the carboxy-terminus part. "
12/13/2007 - "We also demonstrate that the precursor of RET(MEN 2B) interacts with both growth factor receptor-bound protein and Src homology 2 domain-containing already in the ER, and that this interaction is dependent on the kinase activity of RET. "
02/15/2001 - "However, the highly aggressive MEN2B phenotype is not supported by higher levels of Ret-MEN2B kinase activity compared with Ret-MEN2A. "
02/15/2000 - "Thus, while our results support the conclusion that the Met918Thr substitution is responsible for MEN2B, they suggest that the substrate specificity of the RET kinase does not interfere with its normal role in the development of the kidneys and enteric nervous system."
08/01/1998 - "it stimulated ret/MEN2B mitogenic and kinase activities, as well as its ability to phosphorylate Shc, a bona fide Ret substrate. "
01/01/2000 - "Ret kinases are constitutively activated as a result of MEN2A mutations (Ret-MEN2A) or MEN2B mutations (Ret-MEN2B). "
|9.||DNA (Deoxyribonucleic Acid)IBA
12/01/2011 - "Therefore, the present oligoarray can identify the most common M918T mutation of RET oncogene from a variety of DNA sources with good specificity and be a good alternative in the molecular diagnosis for MEN 2B cases."
02/15/1994 - "Sequence analysis of germ-line DNA from MEN 2B patients revealed the existence of the same point mutation in the RET protooncogene in 34 unrelated individuals. "
11/01/2010 - "Multiple Endocrine Neoplasia Type 2B: Early Diagnosis by Multiple Mucosal Neuroma and Its DNA Analysis."
04/01/2006 - "To investigate the possible role of these antioxidative systems in the development of atherosclerosis, expression levels in macrophages from 15 subjects with atherosclerosis (12 men, 3 women) and 15 matched controls (12 men, 3 women) were analyzed using DNA microarrays. "
07/01/2000 - "Members of kindred with either MEN 2A or MEN 2B should be screened by direct DNA testing early in life for mutations in c-Ret. "
|10.||Calcitonin (Calcitonin, Eel)FDA LinkGeneric
01/01/1996 - "The indications for surgery included an elevated basal or stimulated plasma calcitonin level, a positive genetic test result, a thyroid mass, family history of MTC, or a phenotype diagnostic of MEN 2B. "
08/01/1982 - "Two siblings aged 3 and 6 years with MEN 2b, who had elevated plasma calcitonin levels suggesting the presence of MTC are described. "
12/01/1994 - "A policy of routine thyroidectomy in infants with MEN 2B, regardless of serum calcitonin levels, is justified."
11/01/1989 - "This suggests that total thyroidectomy should be performed upon any patient with the characteristic phenotype of MEN IIb, regardless of the results of the stimulation test for calcitonin."
08/01/1982 - "These findings indicate the need for early diagnosis of MEN 2b and the importance of thyroidectomy at the earliest possible age when MTC is suspected by calcitonin screening tests."
11/01/2005 - "Seventeen patients (14 men, 3 women), mean age 58.4 +/- 12.7 years, at 64.5 +/- 26.7 months post-transplant participated in the study. "
01/01/2014 - "At a tertiary care institution, 10 eyelids of 10 patients (7 men, 3 women; mean 56 years, range 24-78) who underwent repair of lower eyelid retraction using a postauricular dermal graft between July 2008 and December 2010 were retrospectively assessed. "
11/01/1999 - "Between December 1984 and December 1994, 16 patients (13 men, 3 women, ranging in age from 37 to 60 years) underwent heterotopic heart transplant at the University of Pittsburgh. "
07/01/1999 - "Twenty-four consecutive heart transplant patients (21 men, 3 women, mean age 55 +/- 11 years) were scanned using double-helical CT. "
08/01/1989 - "Topical CsA 2% was used in 11 high-risk corneal transplant patients (8 men; 3 women; average age, 44 years). "
|2.||Prostatectomy (Retropubic Prostatectomy)
05/01/1994 - "It is the cause of the commonest surgical procedure in older men (3 men in 10 may ultimately undergo prostatectomy). "
06/01/2015 - "The purpose of this study is to study the influence of radical prostatectomy (RP) for prostate cancer on work status and working life in men 3 years after surgery. "
01/01/1999 - "The twelve projects studied included: (1) a mass screening study using PSA as the initial test in 21,079 volunteers; (2) an investigation of the usefulness of normal and age-referenced PSA cut-offs in 1,618 men; (3) a PSA-based screening study of 2,272 asymptomatic blood donors; (4) an investigation of the evidence and significance of transition zone carcinoma in 340 men with negative digital rectal examination findings; (5) determination of percent free PSA in one retrospective and two prospective studies to determine the appropriate cutpoints for percent free PSA; (6) evaluation of the diagnostic benefit of PSA transition zone density in 308 screening volunteers; (7) a study of the impact of PSA-based screening on the percentage of incidental prostate carcinoma in 1, 543 men undergoing transurethral resection of the prostate; (8) an evaluation of the changes in total PSA and pathologic stages in radical prostatectomy over 5 years in a PSA-based mass screening program; (9) a study evaluating the probability of having prostate cancer given the patient's age, total PSA and digital rectal examination findings; (10) an evaluation of the correlation between preoperative predictors and pathologic features in radical prostatectomy specimens; (11) an investigation of the correlation of total PSA with pathologic stage and tumor volume in patients undergoing radical prostatectomy with low PSA cut-off level, and (12) a study whether age has an impact on the extension of prostate cancer. "
07/01/1993 - "In the present study these relationships were explored with nitric oxide synthase immunohistochemistry and reduced nicotinamide adenine dinucleotide phosphate (NADPH) diaphorase histochemistry of select pelvic tissue specimens obtained from 4 men (3 at radical prostatectomy and 1 at autopsy). "
01/01/2015 - "Early recognition of the phenotype of MEN2B syndrome is crucial in order to be able to perform a prophylactic or curative thyroidectomy. "
10/01/2012 - "Without early prophylactic thyroidectomy, the prognosis for patients with MEN 2B is poor; the average age at death is 21 years. "
01/01/2012 - "This case highlights the importance of early prophylactic thyroidectomy in MEN 2B. "
01/01/2012 - "Current guidelines recommend prophylactic thyroidectomy within the first year of life for MEN 2B. "
01/01/2012 - "The surgical treatment of MEN 2B is total thyroidectomy with cervical limphadenectomy of the central compartment of the neck. "
|4.||Homologous Transplantation (Allograft)
06/01/2004 - "Aortic root replacement using a cryopreserved aortic allograft was performed 13 times in 12 patients (9 men, 3 women, mean age 52.8 years) at Saitama Medical School. "
01/01/2005 - "During the 7-year study period, 17 patients (14 men, 3 women; mean age, 68 years) with major peripheral graft infection underwent graft excision and cryopreserved arterial allograft reconstruction. "
10/01/2015 - "A retrospective review of cases was conducted to assess the use of a dehydrated amniotic membrane allograft (DAMA) in a convenience sample of 9 wounds in 8 patients (5 men, 3 women, average age 62 years [range 31-81 years]) with diabetes mellitus and/or vascular disease. "
|5.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
02/01/2003 - "For 10 years, among 2,100 cardiac surgeries, 16 (0.8%) patients (13 men, 3 women; age 49-71 years, mean 62 +/- 9 years) without previous ventricular arrhythmias, with preserved left ventricular ejection fraction, and without acute cause of ventricular arrhythmias, developed VF (n = 4) or a sustained VT between 3 days and 3 weeks after cardiac surgery (coronary artery bypass grafting [n = 6], valve replacement [n = 10]). "
01/01/2012 - "Twenty-five patients (22 men, 3 women) were enrolled in the clinical study, and the following procedures were performed: 1) coronary artery bypass graft (CABG) (n = 9), 2) abdominal aortic graft replacement (n = 4), and 3) peripheral artery bypass (n = 12). "
01/01/2003 - "Eleven consecutive patients (8 men, 3 women; age, 68.14 +/- 10.3 years; left ventricular ejection fraction, 51.17% +/- 18.6%) admitted for coronary artery bypass grafting were equipped with a PiCCO catheter (Pulsion Medical Systems, Munich, Germany) for monitoring of cardiac output (CO), cardiac index (CI), stroke volume (SV), heart rate (HR), and systemic vascular resistance. "